Scopus BioPharma (SCPS) Short Interest Ratio & Short Volume

Short interest is the volume of Scopus BioPharma shares that have been sold short but have not yet been closed out or covered. As of July 31st, traders have sold 10,500 shares of SCPS short. 0.03% of Scopus BioPharma's shares are currently sold short. Learn More on Scopus BioPharma's current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. SCPS shares currently have a short interest ratio of 35.0. Learn More on Scopus BioPharma's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.03% of Scopus BioPharma's floating shares are currently sold short.

0.03% of Scopus BioPharma's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Scopus BioPharma: Navidea Biopharmaceuticals, Inc. (0.00%), Syros Pharmaceuticals, Inc. (0.31%), Virpax Pharmaceuticals, Inc. (0.25%), Evelo Biosciences, Inc. (0.04%), Comera Life Sciences Holdings, Inc. (0.02%), Genocea Biosciences, Inc. (0.33%), Aridis Pharmaceuticals, Inc. (0.05%), Statera Biopharma, Inc. (0.15%), Ampio Pharmaceuticals, Inc. (0.01%), PaxMedica, Inc. (0.01%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($70.87 billion), Invesco QQQ ($30.12 billion), iShares Russell 2000 ETF ($19.85 billion), iShares 20+ Year Treasury Bond ETF ($10.34 billion), MicroStrategy Incorporated ($8.98 billion), iShares iBoxx $ Investment Grade Corporate Bond ETF ($7.61 billion), SPDR S&P Biotech ETF ($6.81 billion), Invesco S&P 500 Equal Weight ETF ($6.14 billion), Palo Alto Networks, Inc. ($5.97 billion), and Super Micro Computer, Inc. ($5.28 billion). View all of the most shorted stocks.

Short selling SCPS is an investing strategy that aims to generate trading profit from Scopus BioPharma as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Scopus BioPharma occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of SCPS, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including SCPS, twice per month. The most recent reporting period available is July, 31 2025.